Phase II study of E7070 in patients with metastatic melanoma (Q35983937)

11 August 2017

Phase II study of E7070 in patients with metastatic melanoma (English)

1 reference

11 August 2017

1 reference

J F Smyth

1

1 reference

11 August 2017

S Aamdal

2

1 reference

11 August 2017

A Awada

3

1 reference

11 August 2017

C Dittrich

4

1 reference

11 August 2017

F Caponigro

5

1 reference

11 August 2017

P Schöffski

6

1 reference

11 August 2017

M Gore

7

1 reference

11 August 2017

T Lesimple

8

1 reference

11 August 2017

N Djurasinovic

9

1 reference

11 August 2017

B Baron

10

1 reference

11 August 2017

M Ravic

11

1 reference

11 August 2017

P Fumoleau

12

1 reference

11 August 2017

C J A Punt

13

1 reference

11 August 2017

EORTC New Drug Development and Melanoma Groups

14

1 reference

11 August 2017

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

16

1 reference

11 August 2017

1

1 reference

11 August 2017

158-161

1 reference

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

11 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI016

Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI016

Quantitative chemical proteomics for identifying candidate drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI016

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI016

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI016

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI016

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDI016

1 reference

11 August 2017

1 reference